1. Scrip
  2. >>Therapy Areas

Takeda/Otsuka bolster GI presence via Japan P-CAB alliance

 
• By Ian Haydock

Otsuka Pharmaceutical is to co-promote in Japan Takeda's potassium-competitive acid blocker (P-CAB) vonoprazan (TAK-438) in an alliance worth JPY20bn ($196m) upfront to the latter company. Otsuka will also pay an undisclosed milestone to its partner on the marketing approval of the drug and receive a percentage of sales following commercialization.

Otsuka Pharmaceutical is to co-promote in Japan Takeda's potassium-competitive acid blocker (P-CAB) vonoprazan (TAK-438) in an alliance worth JPY20bn ($196m) upfront to the latter company. Otsuka will also pay an undisclosed milestone to its partner on the marketing approval of the drug and receive a percentage of sales following commercialization.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.